Kevan M. Shokat

54.8k total citations · 13 hit papers
305 papers, 34.2k citations indexed

About

Kevan M. Shokat is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Kevan M. Shokat has authored 305 papers receiving a total of 34.2k indexed citations (citations by other indexed papers that have themselves been cited), including 237 papers in Molecular Biology, 55 papers in Oncology and 50 papers in Cell Biology. Recurrent topics in Kevan M. Shokat's work include PI3K/AKT/mTOR signaling in cancer (68 papers), Protein Kinase Regulation and GTPase Signaling (46 papers) and Monoclonal and Polyclonal Antibodies Research (26 papers). Kevan M. Shokat is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (68 papers), Protein Kinase Regulation and GTPase Signaling (46 papers) and Monoclonal and Polyclonal Antibodies Research (26 papers). Kevan M. Shokat collaborates with scholars based in United States, United Kingdom and Germany. Kevan M. Shokat's co-authors include Zachary A. Knight, J.M. Ostrem, Chao Zhang, Martin L. Sos, William A. Weiss, Ulf Peters, James A. Wells, Neal Rosen, Kavita Shah and Chao Zhang and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Kevan M. Shokat

297 papers receiving 33.6k citations

Hit Papers

K-Ras(G12C) inhibitors al... 2006 2026 2012 2019 2013 2010 2007 2012 2006 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
    2013 1.7k citations J.M. Ostrem, Kevan M. Shokat et al. profile →
  2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    2010 1.3k citations Kevan M. Shokat et al. profile →
  3. IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response
    2007 1.1k citations Jonathan H. Lin, Han Li et al. Science profile →
  4. The translational landscape of mTOR signalling steers cancer initiation and metastasis
    2012 978 citations Kevan M. Shokat, Davide Ruggero et al. profile →
  5. A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
    2006 940 citations Zachary A. Knight, William A. Weiss et al. profile →
  6. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
    2009 889 citations Zachary A. Knight, Davide Ruggero et al. profile →
  7. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
    2007 765 citations Jimmy A. Blair, Byron Hann et al. profile →
  8. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR
    2008 699 citations Zachary A. Knight, Kevan M. Shokat et al. Proceedings of the National Academy of Sciences profile →
  9. Drugging the 'undruggable' cancer targets
    2017 636 citations Kevan M. Shokat et al. profile →
  10. Targeting the cancer kinome through polypharmacology
    2010 541 citations Zachary A. Knight, Kevan M. Shokat et al. profile →
  11. The unfolded protein response signals through high-order assembly of Ire1
    2008 512 citations Chao Zhang, Kevan M. Shokat et al. profile →
  12. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
    2016 449 citations J.M. Ostrem, Kevan M. Shokat profile →
  13. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells
    2016 280 citations Kevan M. Shokat et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevan M. Shokat United States 96 24.3k 6.9k 5.4k 4.0k 2.7k 305 34.2k
Steven A. Carr United States 108 31.7k 1.3× 5.4k 0.8× 6.3k 1.2× 3.5k 0.9× 2.1k 0.8× 372 44.4k
Nathanael S. Gray United States 104 30.5k 1.3× 10.9k 1.6× 4.0k 0.7× 3.2k 0.8× 2.2k 0.8× 476 42.2k
Edward A. Sausville United States 92 19.3k 0.8× 11.7k 1.7× 3.0k 0.6× 2.3k 0.6× 1.8k 0.6× 329 30.9k
Robert T. Abraham United States 88 20.2k 0.8× 7.5k 1.1× 3.2k 0.6× 5.9k 1.5× 1.9k 0.7× 215 29.0k
Julian Downward United Kingdom 101 30.1k 1.2× 11.4k 1.7× 5.9k 1.1× 5.1k 1.3× 1.9k 0.7× 292 41.7k
Pier Giuseppe Pelicci Italy 106 31.6k 1.3× 9.6k 1.4× 3.4k 0.6× 5.6k 1.4× 2.1k 0.8× 532 45.6k
Dario R. Alessi United Kingdom 124 50.6k 2.1× 7.7k 1.1× 10.1k 1.9× 4.9k 1.2× 5.1k 1.9× 313 65.6k
Neal Rosen United States 100 24.7k 1.0× 12.2k 1.8× 2.4k 0.4× 3.0k 0.7× 1.1k 0.4× 255 34.8k
John Blenis United States 101 39.2k 1.6× 8.2k 1.2× 6.3k 1.2× 6.5k 1.6× 3.7k 1.3× 222 51.9k
Michael D. Waterfield United Kingdom 80 20.8k 0.9× 7.2k 1.0× 5.2k 1.0× 4.3k 1.1× 2.6k 0.9× 187 32.3k

Countries citing papers authored by Kevan M. Shokat

Since Specialization
Citations

This map shows the geographic impact of Kevan M. Shokat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevan M. Shokat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevan M. Shokat more than expected).

Fields of papers citing papers by Kevan M. Shokat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevan M. Shokat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevan M. Shokat. The network helps show where Kevan M. Shokat may publish in the future.

Co-authorship network of co-authors of Kevan M. Shokat

This figure shows the co-authorship network connecting the top 25 collaborators of Kevan M. Shokat. A scholar is included among the top collaborators of Kevan M. Shokat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevan M. Shokat. Kevan M. Shokat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zheng, Qinheng, et al.. (2025). Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells. ACS Chemical Biology. 20(7). 1696–1706.
2.
Shin, Sejeong, Min-Joon Han, Mark P. Jedrychowski, et al.. (2023). mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching. Cell Reports. 42(8). 112868–112868. 16 indexed citations
3.
Guiley, Keelan Z. & Kevan M. Shokat. (2022). A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability. Cancer Discovery. 13(1). 56–69. 57 indexed citations
4.
Pallanck, Leo J., et al.. (2022). Tissue-restricted inhibition of mTOR using chemical genetics. Proceedings of the National Academy of Sciences. 119(38). e2204083119–e2204083119. 4 indexed citations
5.
Wong, Robyn A., Zhenyi An, Daphne A. Haas‐Kogan, et al.. (2019). Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma. Cancer Research. 80(4). 709–718. 17 indexed citations
6.
Shokat, Kevan M., et al.. (2017). INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC. Molecular Cancer Research. 15(6). 765–775. 26 indexed citations
7.
Chen, Ligong, Yan Shu, Xiaomin Liang, et al.. (2014). OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proceedings of the National Academy of Sciences. 111(27). 9983–9988. 182 indexed citations
8.
Maly, Dustin J., Yvan H. Chanthery, Daniel W. Sirkis, et al.. (2014). Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma. Molecular Cancer Therapeutics. 14(2). 419–428. 23 indexed citations
9.
Pourdehnad, Michael, Morgan Truitt, Imran Siddiqi, et al.. (2013). Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proceedings of the National Academy of Sciences. 110(29). 11988–11993. 204 indexed citations
10.
Jang, Miran, Yeonghwan Kim, Hyeran Won, et al.. (2012). Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide. Cancer Research. 72(16). 4214–4224. 25 indexed citations
11.
Barkovich, Krister J., Sujatmi Hariono, Adam L. Garske, et al.. (2012). Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain Cancers. Cancer Discovery. 2(5). 450–457. 39 indexed citations
12.
Ducker, Gregory S., et al.. (2011). The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proceedings of the National Academy of Sciences. 108(37). 15201–15206. 90 indexed citations
13.
Nakamura, Jean L., Emile Pinarbasi, Scott C. Kogan, et al.. (2011). Dose-Dependent Effects of Focal Fractionated Irradiation on Secondary Malignant Neoplasms in Nf1 Mutant Mice. Cancer Research. 71(1). 106–115. 24 indexed citations
14.
Herbert, Shane P., Jan Huisken, Tyson N. Kim, et al.. (2009). Arterial-Venous Segregation by Selective Cell Sprouting: An Alternative Mode of Blood Vessel Formation. Science. 326(5950). 294–298. 243 indexed citations
15.
Wong, Ching Hang, Frederick L. Baehner, Danislav S. Spassov, et al.. (2009). Phosphorylation of the src Epithelial Substrate Trask Is Tightly Regulated in Normal Epithelia but Widespread in Many Human Epithelial Cancers. Clinical Cancer Research. 15(7). 2311–2322. 40 indexed citations
16.
Fan, Qi-Wen, Christine Cheng, Theodore Nicolaides, et al.. (2007). A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN -Mutant Glioma. Cancer Research. 67(17). 7960–7965. 160 indexed citations
17.
Kanin, Elenita I., Ryan Kipp, Charles Kung, et al.. (2007). Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis. Proceedings of the National Academy of Sciences. 104(14). 5812–5817. 93 indexed citations
18.
Lin, Jonathan H., Han Li, Douglas Yasumura, et al.. (2007). IRE1 Signaling Affects Cell Fate During the Unfolded Protein Response. Science. 318(5852). 944–949. 1140 indexed citations breakdown →
19.
Provance, David William, Colleen M. Silan, Luiz Cláudio Cameron, et al.. (2004). Chemical-genetic inhibition of a sensitized mutant myosin Vb demonstrates a role in peripheral-pericentriolar membrane traffic. Proceedings of the National Academy of Sciences. 101(7). 1868–1873. 33 indexed citations
20.
Shimizu, Eiji, Ya‐Ping Tang, Min Cho, et al.. (2003). Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proceedings of the National Academy of Sciences. 100(7). 4287–4292. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven A. Carr Breakdown of academic impact, for papers by Nathanael S. Gray Breakdown of academic impact, for papers by Edward A. Sausville Breakdown of academic impact, for papers by Robert T. Abraham Breakdown of academic impact, for papers by Julian Downward Breakdown of academic impact, for papers by Pier Giuseppe Pelicci Breakdown of academic impact, for papers by Dario R. Alessi Breakdown of academic impact, for papers by Neal Rosen Breakdown of academic impact, for papers by John Blenis Breakdown of academic impact, for papers by Michael D. Waterfield
Rankless by CCL
2026